Mr David MacDonald > Kirkland & Ellis LLP > New York, United States > Lawyer Profile

Kirkland & Ellis LLP
NEW YORK, NY 10022
United States


David MacDonald focuses on intellectual property, pharmaceutical and technology transactions, including joint ventures, consortiums and strategic alliances. He regularly advises pharmaceutical and biotechnology clients on transactional matters, including licensing, marketing and co-promotion, supply and distribution, and other collaboration arrangements. He advises global technology companies on patent strategies, patent and software licensing (including settlement of patent litigation), and monetization (assertion, securitizations, trusts and investment funds). David also advises clients on the intellectual property issues that arise in mergers, acquisitions, divestitures, recapitalizations and bankruptcies. Since 2010, David has been included in Intellectual Asset Management magazine’s list of the world’s top 250 patent and technology licensing lawyers for his “cutting-edge expertise on how patent law issues complicate licensing deals” and his “impressive profile in IT outsourcing.” David has also been included in the IAM Patent 1000 since 2012, which describes him as “one of the pharmaceutical industry’s go-to deal brokers” and says he “manifests a rare faculty for facilitating complex collaborations and transactions between life sciences entities.” David was also highlighted in The Legal 500 United States 2012, 2015, 2017 and 2018 guides to leading U.S. law firms for business. David is the former Chair of the Transactions Involving IP Rights Committee of the ABA.


American Bar Association (Former Chair of the Transactions Involving IP Rights Committee). International Association of Outsourcing Professionals.


Rutgers School of Law at Newark, J.D., High Honors, 1997; Harvard University, B.A., Classics, 1991.

Lawyer Rankings

United States > Intellectual property > Patents: licensing

(Leading lawyers)

David MacDonald – Kirkland & Ellis LLP

Kirkland & Ellis LLP‘s extensive track record acting for licensors and licensees alike nourishes the practice with strong capabilities to negotiate mandates with a deep understanding of both perspectives. In addition to negotiating license agreements, the group is well versed in other commercial arrangements that are often implemented alongside of patent licensing deals, including joint development agreements, supply agreements, and service and technical assistance agreements. The team offers additional expertise in the development and implementation of patent licensing programs, often by way of corporate transactions. Key practitioners include David MacDonald in New York, who has a focus on pharmaceutical and biotechnology companies; Chicago-based trio Russell Levine, Adam Petravicius, and Seth Traxler, who leads the technology & IP transactions practice; and Shellie Freedman in New York, whose background in molecular and cell biology provides her with additional insight into life sciences transactions.